Business
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory
About this update from Scynexis, Inc.
[{"type":"text","content":"Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infectionsFindings indicate oral ibrexafungerp could potentially decrease length of hospital stays by reducing dependence on IV-administered antifungals JERSEY CITY, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the publication of six abstracts in the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) abstract book, now available online.\n “We are pleased to have six abstracts accepted and presented in the 30th ECCMID abstract book. Cumulatively, the body of work presented in these abstracts provides evidence to support ibrexafungerp’s potential clinical utility, from vaginal yeast infections to life-threatening refractory invasive fungal infections, including resistant organisms, like Candida auris,” said Marco Taglietti, M.D., Chief Executive Officer of SCYNEXIS. “We appreciate ECCMID’s efforts to support scientific progress by publishing these abstracts in the absence of the conference, especially at a time when there is heightened awareness of infectious diseases and their devastating impact on global public health. The current COVID-19 pandemic reinforces the need to continually develop new anti-infectives and prepare for the next emerging threat.” Abstract details: Title: Abstract #:Author: Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)9710Barbara D. Alexander, MD, Duke UniversityHighlights: An interim analysis of 41 patients from the Phase 3 clinical study evaluating ibrexafungerp for the treatment of patients with refractory candidiasis or patients who were intolerant to the standard of care (FURI Study) found that 83% of the patients achieved a clinical benefit (including 56% with complete or partial response and 27% with stable disease), compared to 15% with disease progression. One patient was categorized as indeterminate. Ibrexafungerp was well-tolerated with the most common treatment-related adverse events being of gastrointestinal origin.Link: Please scro...